Adults over 50 experienced fewer influenza-like illnesses with experimental mRNA vaccine compared to standard jabs, according to phase 3 trial results published in leading medical journal.
A new type of influenza vaccine using mRNA technology has demonstrated superior protection against flu-like illness in adults aged 50 and older, according to results from a major clinical trial published by researchers.
The phase 3 Fluent trial found that participants who received the experimental mRNA influenza vaccine experienced fewer cases of confirmed influenza-like illness compared to those given standard flu vaccines. However, the study also revealed that recipients of the mRNA vaccine reported higher rates of side effects following vaccination.
The Trial Results
The findings, published in the New England Journal of Medicine, represent the latest development in mRNA vaccine technology – the same approach used successfully in COVID-19 vaccines during the pandemic. The research focused specifically on adults aged 50 and above, a demographic that faces higher risks from seasonal influenza.
According to the published results, the mRNA vaccine showed measurably better performance in preventing confirmed cases of influenza-like illness when compared against conventional seasonal flu vaccines currently in use.
Side Effects More Frequent
Yet the improved protection came with a trade-off. Trial participants who received the mRNA influenza vaccine experienced what researchers term “higher reactogenicity” – medical terminology for more frequent or pronounced side effects after vaccination.
The study did not specify the exact nature or severity of these additional side effects in the initial announcement of results.
What the Science Shows
Seasonal influenza affects millions of people annually, with older adults facing particular vulnerability to severe complications. Current flu vaccines require annual updates to match circulating virus strains, with effectiveness varying year to year.
The mRNA approach offers potential advantages in vaccine development speed and adaptability. This technology allows researchers to modify vaccine formulations more rapidly when new flu strains emerge.
Source: @NEJM
Key Takeaways
- Adults over 50 had fewer confirmed flu-like illnesses with mRNA vaccine versus standard vaccines
- Side effects occurred more frequently with the experimental mRNA vaccine
- Results come from completed phase 3 Fluent trial published in medical journal
What This Means for Kent Residents
Kent residents should continue receiving their annual flu vaccinations through existing NHS programmes while this research undergoes regulatory review. The experimental mRNA flu vaccine remains unavailable to the public pending further safety evaluation and potential approval by UK medicines regulators. Anyone with questions about seasonal flu vaccination should contact their GP surgery or call NHS 111 for guidance on current vaccine options available locally.